drugset
drugset / Trial / NCT04776694

Compassionate Use of Dupilumab

NCT04776694 ↗

Expanded access Approved for marketing Regeneron Pharmaceuticals

Summary

Provide Compassionate Use of Dupilumab

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Dupilumab Monoclonal antibody — —

Indications

type II hypersensitivity reaction disease